Russell Investments Group
ABOS icon

Russell Investments Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Russell Investments Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-278
Closed -$306 – 3839
2025
Q1 		$306 Sell
278
-959
-78% -$1.37K ﹤0.01% 3715
2024
Q4 		$2.13K Buy
+1,237
New +$2.98K ﹤0.01% 3434

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Russell Investments Group's ABOS Position: Q2 2025 in Review

Russell Investments Group sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 278 shares — an estimated $306 sold.

Russell Investments Group first reported a position in ABOS in Q4 2024 and held it in 2 quarters. The position peaked at $2.13K in Q4 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • Russell Investments Group reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Russell Investments Group sold 278 Acumen Pharmaceuticals shares in Q2 2025, an estimated $306.
  • Russell Investments Group first reported a position in Acumen Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Russell Investments Group's Acumen Pharmaceuticals position peaked at $2.13K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on Russell Investments Group's 13F filing for Q2 2025, filed 13 Aug 2025.